AVA 4746
Alternative Names: AVA4746; TBC 4746Latest Information Update: 22 Feb 2023
At a glance
- Originator Encysive Pharmaceuticals
- Developer Aviara Pharmaceuticals; Encysive Pharmaceuticals; Pfizer; Schering-Plough
- Class Small molecules
- Mechanism of Action Integrin alpha4beta1 antagonists; Vascular cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Stem cell mobilisation
- Discontinued Asthma; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 22 Feb 2023 Preclinical development is ongoing in Stem cell mobilisation in USA (unspecified route) (Aviara Pharmaceuticals pipeline, February 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Stem-cell-mobilisation in USA
- 17 Jan 2017 Preclinical trials in Stem cell mobilisation in USA (unspecified route)